Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
Ohio State University Comprehensive Cancer Center
Ohio State University Comprehensive Cancer Center
TG Therapeutics, Inc.
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)
Case Comprehensive Cancer Center
City of Hope Medical Center